Zofran, a drug produced and marketed by GlaxoSmithKline, acts as an anti-nausea and anti-vomiting medication for post-surgery patients. The drug was approved in the United States in 1991 exclusively for use with chemotherapy patients and post surgery patients. Zofran is also often prescribed off-label to pregnant women with morning sickness.
The FDA issued an updated warning for Zofran in 2012 after studies concluded that the drug may cause an increased risk of heart complications in some patients. In 2013, Danish studies showed that Zofran can be linked to an increase in potential birth defects in pregnant women. These birth defects can include kidney problems, developmental issues, but, most commonly, it is proven to cause up to a 2.4 fold increase in risk for cleft lip and cleft palate in developing fetuses.
In 2012 the Department of Justice announced that GlaxoSmithKline had agreed to pay a $3 billion settlement. The details of the settlement include allegations that GlaxoSmithKline illegally marketed Zofran for off label uses, specifically to pregnant women, and paid doctors to prescribe Zofran and push it for off label uses.
The attorneys and staff at Jones Brown are determined to help clients recover losses. It is important to understand that the plaintiff’s personal doctor is not held responsible in medical lawsuits. If you or someone you know has experienced heart issues or pregnancy complications including birth defects, you may be eligible to recover losses relating to medical expenses or pain and suffering. To find out if you qualify to file a claim, fill out our brief questionnaire.